Our team in the Pulmonary Hypertension Program at Boston Children's Hospital is actively involved in therapeutic trials of new therapies for pulmonary hypertension. We’ve participated in prospective trials of inhaled nitric oxide, sildenafil, bosentan and ambrisentan. Our current therapeutic trials include:
- evaluation of a new, more efficient way of delivering inhaled iloprost
- study of the long-term effects of sildenafil and ambrisentan
We are also exploring new ways of evaluating the lung’s blood vessels to help us better design therapy.